MGN-3 Research Data

MGN-3 Research Abstract 

CLINICAL RESEARCH USING MGN-3

(Arabinoxylane Compound)

NK IMMUNOMODULATORY FUNCTION IN 27 CANCER PATIENTS BY  MGN-3, A MODIFIED ARABINOXYLANE FROM RICE BRAN

Ghoneum M, Namatalla G.

87th Annual Meeting of the American Association for Cancer Research  April 20-24,1996 Washington, DC

MGN-3 immunomodulatory function was examined in 27 cancer patients. MGN-3 is an arabinoxylane from rice bran that has enzymatically modified by hyphomycetes mycelia. The patients had different types of advanced malignancies: 

7 patients had breast cancer, 

7 prostate cancer, 

8 multiple myelome (MM), 

3 leukemia, and 

2 cervical cancer.

All patients were under treatment with conventional therapy and were also given 3g of MGN-3 daily. NK activity was examined at 2 weeks, 3 months and 6 months. Activity of NK cells was examined by 5lCr-release assay using K562 tumor cells as targets, at effector:target ratios from 12:1- 100:1.

Results showed that:

I ) Patients had low level of basal NK activity (10.8-40%),

2) treatment with MGN-3 caused a remarkable increase in NK activity at 2 weeks. The percentages of induction were as follows: breast Ca 154-332%, prostatic 174-384%, leukemia 100-240%,MM 100-537%, and cervical CA 100-275%,

3) enhancement of NK activity continues to rise at 3 and 6 rnonths after treatment.

We concluded that the high augmentory effect of MGN-3 makes it a promising immunotherapeutic agent for treatment of cancer.

Back to MGN-3 index
 

 

---

Support Research-Data.com Free Information 
Click On Our Recommended Sponsors